SwePub
Sök i SwePub databas

  Extended search

Träfflista för sökning "WFRF:(Ruda M) "

Search: WFRF:(Ruda M)

  • Result 1-10 of 30
Sort/group result
   
EnumerationReferenceCoverFind
1.
  •  
2.
  •  
3.
  •  
4.
  • O'Donoghue, M. L., et al. (author)
  • Effect of Losmapimod on Cardiovascular Outcomes in Patients Hospitalized With Acute Myocardial Infarction: A Randomized Clinical Trial
  • 2016
  • In: Jama. - : American Medical Association (AMA). - 0098-7484. ; 315:15, s. 1591-9
  • Journal article (peer-reviewed)abstract
    • IMPORTANCE: p38 Mitogen-activated protein kinase (MAPK)-stimulated inflammation is implicated in atherogenesis, plaque destabilization, and maladaptive processes in myocardial infarction (MI). Pilot data in a phase 2 trial in non-ST elevation MI indicated that the p38 MAPK inhibitor losmapimod attenuates inflammation and may improve outcomes. OBJECTIVE: To evaluate the efficacy and safety of losmapimod on cardiovascular outcomes in patients hospitalized with an acute myocardial infarction. DESIGN, SETTING, AND PATIENTS: LATITUDE-TIMI 60, a randomized, placebo-controlled, double-blind, parallel-group trial conducted at 322 sites in 34 countries from June 3, 2014, until December 8, 2015. Part A consisted of a leading cohort (n = 3503) to provide an initial assessment of safety and exploratory efficacy before considering progression to part B (approximately 22,000 patients). Patients were considered potentially eligible for enrollment if they had been hospitalized with an acute MI and had at least 1 additional predictor of cardiovascular risk. INTERVENTIONS: Patients were randomized to either twice-daily losmapimod (7.5 mg; n = 1738) or matching placebo (n = 1765) on a background of guideline-recommended therapy. Patients were treated for 12 weeks and followed up for an additional 12 weeks. MAIN OUTCOMES AND MEASURES: The primary end point was the composite of cardiovascular death, MI, or severe recurrent ischemia requiring urgent coronary revascularization with the principal analysis specified at week 12. RESULTS: In part A, among the 3503 patients randomized (median age, 66 years; 1036 [29.6%] were women), 99.1% had complete ascertainment for the primary outcome. The primary end point occurred by 12 weeks in 123 patients treated with placebo (7.0%) and 139 patients treated with losmapimod (8.1%; hazard ratio, 1.16; 95% CI, 0.91-1.47; P = .24). The on-treatment rates of serious adverse events were 16.0% with losmapimod and 14.2% with placebo. CONCLUSIONS AND RELEVANCE: Among patients with acute MI, use of losmapimod compared with placebo did not reduce the risk of major ischemic cardiovascular events. The results of this exploratory efficacy study did not justify proceeding to a larger efficacy trial in the existing patient population. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT02145468.
  •  
5.
  •  
6.
  • Scirica, B. M., et al. (author)
  • Patients with acute coronary syndromes and elevated levels of natriuretic peptides: the results of the AVANT GARDE-TIMI 43 Trial
  • 2010
  • In: European Heart Journal. - 0195-668X. ; 31:16, s. 1993-2005
  • Journal article (peer-reviewed)abstract
    • Aims Elevated natriuretic peptides (NPs) are associated with an increased cardiovascular risk following acute coronary syndromes (ACSs). However, the therapeutic implications are still undefined. We hypothesized that early inhibition of renin-angiotensin-aldosterone system (RAAS) in patients with preserved left ventricular function but elevated NPs but following ACS would reduce haemodynamic stress as reflected by a greater reduction NP compared with placebo. Methods and results AVANT GARDE-TIMI 43 trial, a multinational, double-blind trial, randomized 1101 patients stabilized after ACS without clinical evidence of heart failure or left ventricular function
  •  
7.
  •  
8.
  •  
9.
  •  
10.
  •  
Skapa referenser, mejla, bekava och länka
  • Result 1-10 of 30
Type of publication
journal article (24)
conference paper (3)
research review (2)
other publication (1)
Type of content
peer-reviewed (24)
other academic/artistic (5)
pop. science, debate, etc. (1)
Author/Editor
Widmalm, Göran (4)
Henriksson, Roger (4)
Soffietti, Riccardo (3)
Korotkova, Natalia (3)
Maccarrone, M (3)
D'Addario, C (3)
show more...
Singh, B (3)
Varma, S (3)
Brumer, Harry (3)
Bergman, Jan (3)
Hu, D. (2)
Li, Y. (2)
Liu, Y. (2)
Bose, S. (2)
Diaz, R. (2)
Dellborg, M (2)
Alexander, J (2)
Weiss, R. (2)
Huang, J. (2)
Chen, J. (2)
Thomas, J. (2)
Pearce, M. (2)
Osborne, J. (2)
Anderson, J. (2)
Medina, F (2)
Kis, E. (2)
Thompson, P. (2)
Roy, M (2)
Ruda, Alessandro, 19 ... (2)
Willis, J. (2)
Wu, J (2)
Salomone, S (2)
Smith, K. (2)
Berger, C (2)
Henderson, D (2)
Verheugt, FWA (2)
Rodriguez, A (2)
Ferrari, E. (2)
LOPEZ, C (2)
Rodriguez, M (2)
Li, Jian (2)
Preusser, M (2)
Samad, B (2)
Wågberg, Lars, 1956- (2)
Phillips, M. (2)
Dong, Y. (2)
Anderson, R (2)
Di Marzo, V (2)
Kiss, R (2)
González, E. (2)
show less...
University
Karolinska Institutet (12)
Royal Institute of Technology (6)
Umeå University (4)
Stockholm University (4)
University of Gothenburg (3)
Södertörn University (3)
show more...
Chalmers University of Technology (2)
Uppsala University (1)
Lund University (1)
Swedish University of Agricultural Sciences (1)
show less...
Language
English (30)
Research subject (UKÄ/SCB)
Natural sciences (12)
Medical and Health Sciences (9)
Engineering and Technology (2)

Year

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view